NCT01886859 2022-09-26Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNational Cancer Institute (NCI)Phase 1 Completed27 enrolled